A protein that is a key modulator of fat, glucose and cholesterol levels in the body usually works in tandem with another ...
Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review ...
Nuvalent (NASDAQ:NUVL) executives highlighted ongoing regulatory milestones for the company’s lead oncology programs and ...
Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...
Zidesamtinib targets ROS1-positive NSCLC, showing promise in overcoming resistance mutations and CNS metastases with brain penetrance. The ARROS-1 trial demonstrated significant response rates in TKI ...
Zidesamtinib is an investigational, novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is ...
Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC On track to report topline pivotal data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC ...
Alaska Air (NYSE: ALK) has experienced a challenging year, with its price declining by 15% and notably lagging behind both the S&P 500’s 15% increase and its competitors. This downturn can be ...
About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results